Immunological responses during a virologically failing antiretroviral regimen are associated with in vivo synonymous mutation rates of HIV type-1 env

Abstract

Background

Little is known about the underlying causes of differences in immunological response to antiretroviral therapy during multidrug-resistant (MDR) HIV type-1 (HIV-1) infection. This study aimed to identify virological factors associated with immunological response during therapy failure.

Methods

Individuals with MDR HIV-1 receiving therapy for ≥3 months were included. CD4⁺ T-cell count slopes and pol and clonal env sequences were determined. Genetic analyses were performed using distance-based and maximum likelihood methods. Synonymous mutations rates of env were used to estimate viral replication.

Results

Of 1,000 patients treated between 1995 and 2003, 72 individuals fulfilled the definition for triple-class failure, but 25 were non-compliant, 21 were successfully resuppressed and 3 had died or quit therapy. Of the 23 that fulfilled study criteria, 16 had samples available for analysis. In a longitudinal mixed-effects model, plasma HIV-1 RNA only tended to predict immunological response (P=0.06), whereas minor protease inhibitor (PI) and nucleoside reverse transcriptase (NRTI) mutations at baseline correlated significantly with CD4⁺ T-cell count slopes (r=-0.56, P=0.04 and r=-0.64, P=0.008, respectively). Interestingly, synonymous mutations of env correlated inversely with CD4⁺ T-cell count slopes (r=-0.60; P=0.01) and individuals with codons under positive selection had significantly better CD4⁺ T-cell responses than individuals without (0.42 versus -5.34; P=0.02).

Conclusions

Our results suggest that minor PI mutations and NRTI mutations present early during therapy failure are predictive of the CD4⁺ T-cell count slopes. Synonymous mutation rates of the env gene suggested that underlying differences in fitness could cause this association.

References

Egger

, May

, Chene

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.

Lancet 2002; 360: 119–129.

Palella

F.J.

, Delaney

K.M.

, Moorman

A.C.

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection.

N Engl J Med 1998; 338: 853–860.

Pillay

The emergence and epidemiology of resistance in the nucleoside-experienced HIV-infected population.

Antivir Ther 2001; 6 Suppl 3: 15–24.

The PLATO Collaboration.

Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes.

Lancet 2004; 364: 51–62.

Gandhi

, Wei

, Amin

, Kazanjian

Effect of maintaining highly active antiretroviral therapy on AIDS events among patients with late-stage HIV infection and inadequate response to therapy.

Clin Infect Dis 2006; 42: 878–884.

Kaufmann

, Pantaleo

, Sudre

, Telenti

, SWISS HIV Cohort Study. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study. Lancet 1998; 351: 723–724.

Lecossier

, Bouchonnet

, Schneider

, Clavel

, Hance

A.J.

, Centre de Recherche Integre sur le VIH Bichat–Claude Bernard. Discordant increases in CD4⁺ T cells in human immunodeficiency virus-infected patients experiencing virologic treatment failure: role of changes in thymic output and T cell death. J Infect Dis 2001; 183: 1009–1016.

Perrin

, Telenti

HIV treatment failure: testing for HIV resistance in clinical practice.

Science 1998; 280: 1871–1873.

Piketty

, Castiel

, Belec

Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease.

AIDS 1998; 12: 745–750.

10.

Gandhi

, Nagappan

, Cinti

, Wei

, Kazanjiaz

Long-term immunologic and virologic responses in patients with highly resistant HIV infection who are treated with an incompletely suppressive antiretroviral regimen.

Clin Infect Dis 2007; 45: 1085–1092.

11.

Barbour

J.D.

, Grant

R.M.

The clinical implications of reduced viral fitness.

Curr Infect Dis Rep 2004; 6: 151–158.

12.

Price

D.A.

, Scullard

, Oxenius

Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity.

J Virol 2003; 77: 6041–6049.

13.

Solomon

, Lane

, Wightman

, Gorry

, Lewin

Enhanced replicative capacity and pathogenicity of HIV-1 isolated from individuals infected with drug-resistant virus and declining CD4⁺ T-cell counts.

J Acquir Immune Defic Syndr 2005; 40: 140–148.

14.

Lemey

, Kosakovsky Pond

S.L.

, Drummond

A.J.

Synonymous substitution rates predict HIV disease progression as a result of underlying replication dynamics.

PLoS Comput Biol 2007; 3: e29.

15.

Lohse

, Obel

, Kronborg

Declining risk of triple-class antiretroviral drug failure in Danish HIV-infected individuals.

AIDS 2005; 19: 815–822.

16.

Jorgensen

L.B.

, Christensen

M.B.

, Gerstoft

Prevalence of drug resistance mutations and non-B subtypes in newly diagnosed HIV-1 patients in Denmark.

Scand J Infect Dis 2003; 35: 800–807.

17.

Van Laethem

, Schrooten

, Dedecker

A genotypic assay for the amplification and sequencing of gag and protease from diverse human immunodeficiency virus type 1 group M subtypes.

J Virol Methods 2006; 132: 181–186.

18.

Ibis Biosciences. Bioedit version 7.0.9. (Updated 27 June 2007. Accessed January 2008.) Available from http://www.mbio.ncsu.edu/BioEdit/BioEdit.html.

19.

Johnson

V.A.

, Brun-Vezinet

, Clotet

Update of the drug resistance mutations in HIV-1: spring 2008.

Top HIV Med 2008; 16: 62–68.

20.

Van Laethem

, De Luca

L.A.

, Antinori

, Cingolani

, Perna

C.F.

, Vandamme

A.M.

A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients.

Antivir Ther 2002; 7: 123–129.

21.

Stanford University. The Stanford HIV drug resistance database. (Accessed September 2008.) Available from http://hivdb.stanford.edu.

22.

Tamura

, Dudley

, Nei

, Kumar

MEGA4: molecular evolutionary genetics analysis (MEGA) software version 4.0.

Mol Biol Evol 2007; 24: 1596–1599.

23.

Nei

, Gojobori

Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions.

Mol Biol Evol 1986; 3: 418–426.

24.

Rozas

, Sanchez-DelBarrio

J.C.

, Messeguer

, Rozas

DnaSP, DNA polymorphism analyses by the coalescent and other methods.

Bioinformatics 2003; 19: 2496–2497.

25.

Kosakovsky Pond

S.L.

, Frost

S.D.W.

, Muse

S.V.

HyPhy: hypothesis testing using phylogenies.

Bioinformatics 2005; 21: 676–679.

26.

Kosakovsky Pond

S.L.

, Frost

S.D.W.

Datamonkey: rapid detection of selective pressure on individual sites of codon alignments.

Bioinformatics 2005; 21: 2531–2533.

27.

W.H.

, Tanimura

, Sharp

P.M.

Rates and dates of divergence between AIDS virus nucleotide sequences.

Mol Biol Evol 1988; 5: 313–330.

28.

Hudson

R.R.

, Boos

D.D.

, Kaplan

N.L.

A statistical test for detecting geographic subdivision.

Mol Biol Evol 1992; 9: 138–151.

29.

Achaz

, Palmer

, Kearney

A robust measure of HIV-1 population turnover within chronically infected individuals.

Mol Biol Evol 2004; 21: 1902–1912.

30.

Atlier de BioInformatique – Universite Paris VI. Non-parametric test for panmixia. (Accessed November 2008.) Available from http://wwwabi.snv.jussieu.fr/∼achaz/hudsontest.html.

31.

Los Alamos HIV sequence database. (Accessed November 2008.) Available from http://www.hiv.lanl.gov/content/sequence/HYPERMUT/hypermut.html.

32.

Menzo

, Monachetti

, Balotta

Processivity and drug-dependence of HIV-1 protease: determinants of viral fitness in variants resistant to protease inhibitors.

AIDS 2003; 17: 663–671.

33.

Martinez-Picado

, Savara

A.V.

, Sutton

, D'Aquila

R.T.

Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1.

J Virol 1999; 73: 3744–3752.

34.

Ridky

, Leis

Development of drug resistance to HIV-1 protease inhibitors.

J Biol Chem 1995; 270: 29621–29623.

35.

Nijhuis

, Deeks

, Boucher

Implications of antiretroviral resistance on viral fitness.

Curr Opin Infect Dis 2001; 14: 23–28.

36.

Nijhuis

, Schuurman

, de Jong

Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy.

AIDS 1999; 13: 2349–2359.

37.

Kimura

Evolutionary rate at the molecular level.

Nature 1968; 217: 624–626.

38.

Hsu

, Inouye

, Rezende

Higher fidelity of RNA-dependent DNA mispair extension by M184V drug-resistant than wild-type reverse transcriptase of human immunodeficiency virus type 1.

Nucleic Acids Res 1997; 25: 4532–4536.

39.

Wainberg

M.A.

, Drosopoulos

W.C.

, Salomon

Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase.

Science 1996; 271: 1282–1285.

40.

Pandey

V.N.

, Kaushik

, Rege

, Sarafanos

S.G.

, Yadav

P.N.S.

, Modak

M.J.

Role of methionine 184 of human immunodeficiency virus type-1 reverse transcriptase in the polymerase function and fidelity of DNA synthesis.

Biochemistry 1996; 35: 2168–2179.

41.

Nijhuis

, Boucher

C.A.B.

, Schipper

, Leitner

, Schuurman

, Albert

Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy.

Proc Natl Acad Sci U S A 1998; 95: 14441–14446.

42.

Kitrinos

K.M.

, Nelson

J.A.E.

, Resch

, Swanstorm

Effect of a protease inhibitor-induced genetic bottleneck on human immunodeficiency virus type 1 env gene populations.

J Virol 2005; 79: 10627–10637.

43.

Renaud

, Katlama

, Mallet

Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimen.

AIDS 1999; 13: 669–676.

44.

Deeks

S.G.

, Barbour

J.D.

, Grant

R.M.

, Martin

J.N.

Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia.

AIDS 2002; 16: 201–207.

45.

Deeks

S.G.

, Martin

J.N.

, Sinclair

Strong cell-mediated immune responses are associated with the maintenance of low-level viremia in antiretroviral-treated individuals with drug-resistant human immunodeficiency virus type 1.

J Infect Dis 2004; 189: 312–321.

46.

Emu

, Sinclair

, Favre

Phenotypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment.

J Virol 2005; 79: 14169–14178.

47.

Napravnik

, Edwards

, Stewart

, Stalzer

, Matteson

, Eron

J.J.

Jr. , HIV-1 drug resistance evolution among patients on potent combination antiretroviral therapy with detectable viremia. J Acquir Immune Defic Syndr 2005; 40: 34–40.

48.

Kantor

, Shafer

R.W.

, Follansbee

Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy.

AIDS 2004; 18: 1503–1511.

49.

Hatano

, Hunt

, Weidler

Rate of viral evolution and risk of losing future drug options in heavily pretreated, HIV-infected patients who continue to receive a stable, partially suppressive treatment regimen.

Clin Infect Dis 2006; 43: 1329–1336.